Genetic Polymorphisms and Plasma Levels of Interleukin-22 Contribute to the Development of Nonsmall Cell Lung Cancer

2014 ◽  
Vol 33 (10) ◽  
pp. 705-714 ◽  
Author(s):  
Fei Liu ◽  
Xufeng Pan ◽  
Lin Zhou ◽  
Jian Zhou ◽  
Bin Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Genetic Polymorphisms ◽  
Cell Lung Cancer ◽  
Plasma Levels ◽  
Nonsmall Cell Lung Cancer ◽  
Interleukin 22

scholarly journals Interleukin-22 receptor is overexpressed in nonsmall cell lung cancer and portends a poor prognosis

2016 ◽  
Vol 47 (4) ◽  
pp. 1277-1280 ◽  
Author(s):  
Antoine Guillon ◽  
Fabien Gueugnon ◽  
Konstantinos Mavridis ◽  
Emilie Dalloneau ◽  
Youenn Jouan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Poor Prognosis ◽  
Nonsmall Cell Lung Cancer ◽  
Interleukin 22

Genetic polymorphisms ofMDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk

2008 ◽  
Vol 122 (4) ◽  
pp. 915-918 ◽  
Author(s):  
Geoffrey Liu ◽  
Paul Wheatley-Price ◽  
Wei Zhou ◽  
Sohee Park ◽  
Rebecca S. Heist ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Risk ◽  
Cigarette Smoking ◽  
Genetic Polymorphisms ◽  
Cell Lung Cancer ◽  
Lung Cancer Risk ◽  
Nonsmall Cell Lung Cancer

scholarly journals Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy

2021 ◽  
Vol 9 (3) ◽  
pp. e002262
Author(s):  
Justin Ferdinandus ◽  
Martin Metzenmacher ◽  
Lukas Kessler ◽  
Lale Umutlu ◽  
Clemens Aigner ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Metabolic Response ◽  
Standard Of Care ◽  
Nonsmall Cell Lung Cancer ◽  
Published Data ◽  
Complete Metabolic Response ◽  
Positron Emission ◽  
Checkpoint Inhibitor Therapy

IntroductionImmunotherapy is the new standard of care in advanced nonsmall cell lung cancer (NSCLC). Recently published data show that treatment discontinuation after 12 months of nivolumab treatment is associated with shorter survival. Therefore, the ideal duration of immunotherapy remains unclear, and finding markers of beneficial outcomes is of great importance. Here, we determine the proportion of complete metabolic responses (CMR) in patients who have not progressed after 24 months of immunotherapy.MethodsThis is a retrospective analysis of 45 patients with positron emission tomography using 2-[18F]fluoro-2-deoxy-D-glucose imaging for assessment of residual metabolic activity after at least 24 months. CMR was defined as uptake in tumor lesions below background levels, using mediastinum as a reference. ResultsOut of 45 patients, 29 patients had a CMR (64%). CMR was observed more frequently in non-first-line patients. Patients with CMR were younger (median 65.7 vs 75.5, p=0.03). Fourteen patients with CMR have discontinued therapy and have not progressed until time of analysis; however, median follow-up was only 5.6 (range 0.8–17.0) months.ConclusionAfter a minimum of 24 months of palliative immunotherapy for NSCLC, CMR occurred in almost two thirds of patients. Potentially, achievement of CMR might identify patients, for whom palliative immunotherapy may be safely discontinued.

scholarly journals Aberrantp16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer

2003 ◽  
Vol 106 (6) ◽  
pp. 913-918 ◽  
Author(s):  
Sonata Jarmalaite ◽  
Annamaria Kannio ◽  
Sisko Anttila ◽  
Juozas R. Lazutka ◽  
Kirsti Husgafvel-Pursiainen
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Promoter Methylation ◽  
Nonsmall Cell Lung Cancer ◽  
Former Smokers
Sign in / Sign up

Export Citation Format

Share Document